RET G810 Solvent-Front Mutations and Selpercatinib Resistance

Selective RET inhibitors selpercatinib and pralsetinib have transformed treatment for RET fusion–positive non-small cell lung cancer and medullary thyroid cancer. Acquired resistance inevitably emerges, and solvent-front mutations at glycine 810 now represent a recognized mechanism. Unlike gatekeeper mutations, solvent-front substitutions alter the architecture of the ATP-binding pocket's solvent-exposed region, disrupting inhibitor binding through distinct structural mechanisms.

RET Fusions and Selective RET Inhibitors

RET rearrangements drive approximately 1–2% of non-small cell lung cancers and occur in other malignancies including thyroid and colorectal cancers. RET fusion proteins retain the intracellular kinase domain but lose autoinhibitory N-terminal elements, resulting in constitutive kinase activity. Multi-kinase inhibitors with RET activity—cabozantinib, vandetanib, lenvatinib—provided initial therapeutic options but carry substantial off-target toxicity.

Selpercatinib and pralsetinib are ATP-competitive type I inhibitors engineered for RET selectivity. Both bind the DFG-in active conformation and exploit the specific geometry of RET's ATP-binding site. Clinical responses in RET fusion–positive NSCLC exceed 60% overall response rates, with particularly strong activity in treatment-naive patients and those with CNS involvement. However, progression occurs with a median duration of response typically between 17 and 24 months, and on-target kinase domain mutations account for a substantial fraction of resistance cases.

The RET Solvent-Front: Structural Context

Glycine 810 sits at the solvent-front region of the RET kinase ATP-binding pocket, positioned where the inhibitor-binding site interfaces with bulk solvent. This residue lies on the same β-strand as the gatekeeper residue V804, but occupies a distinct structural niche. The solvent-front is defined by residues that line the ATP pocket's solvent-accessible edge, including positions that tolerate glycine's conformational flexibility in the wild-type enzyme.

In the RET active-site architecture, G810 resides in a region that accommodates inhibitor substituents extending toward solvent-exposed space. The small side chain of glycine permits inhibitor binding modes that would clash with larger residues. Selective RET inhibitors exploit this pocket geometry: selpercatinib and pralsetinib both position hydrophobic or heteroaromatic groups in regions immediately adjacent to G810.

G810R and G810S: Mutation Spectrum

RET G810R represents the most frequently observed solvent-front substitution in patients progressing on selpercatinib or pralsetinib. The glycine-to-arginine change introduces a large, positively charged side chain that projects into the inhibitor-binding site. Structural modeling and biochemical studies indicate that the arginine guanidinium group creates severe steric clash with inhibitor moieties, particularly affecting compounds that rely on tight packing in the solvent-front region.

G810S mutations have also been reported, though less frequently. Serine substitution is more conservative—introducing a hydroxyl-bearing side chain—but still sufficient to perturb inhibitor binding by altering local electrostatics and introducing steric bulk where the wild-type pocket is unencumbered. The hydroxyl group may also create unfavorable interactions with hydrophobic inhibitor substituents.

Importantly, G810 mutations differ mechanistically from the RET gatekeeper mutation V804M/L. Gatekeeper mutations obstruct inhibitor binding by directly blocking access to the hydrophobic back pocket, whereas solvent-front mutations disrupt binding at the pocket's entrance and solvent-interface region. This distinction has implications for inhibitor design and resistance profiling.

Resistance Phenotype and Clinical Context

Preclinical studies demonstrate that RET G810R confers high-level resistance to both selpercatinib and pralsetinib. Biochemical IC₅₀ values shift 10- to 100-fold depending on assay format, and cellular transformation assays show robust resistance in the presence of clinically relevant inhibitor concentrations. Patients harboring G810R at progression exhibit loss of response with subsequent tumor growth despite continued therapy.

G810 mutations have been identified in circulating tumor DNA from patients with RET fusion–positive NSCLC who initially responded to selective RET inhibitors. The mutations emerge under selective pressure, often as polyclonal resistance where multiple distinct kinase domain mutations coexist. Co-occurrence with other resistance mechanisms—including gatekeeper mutations, bypass pathway activation, or histologic transformation—adds complexity to the resistance landscape.

No approved therapies specifically overcome RET G810R resistance. Some preclinical data suggest that next-generation RET inhibitors or multi-kinase inhibitors may retain partial activity, but clinical validation is lacking. Rational combination strategies targeting both RET and parallel survival pathways represent an area of active investigation.

Modeling RET G810 Mutations in Liganx

Understanding solvent-front resistance requires examining how mutations reshape inhibitor-kinase interactions at atomic resolution. Liganx enables mutation-aware docking of selpercatinib, pralsetinib, or experimental RET inhibitors into both wild-type RET and G810-mutant models. You can introduce G810R or G810S substitutions, then dock ligands to visualize steric clashes, altered hydrogen-bonding networks, and changes in binding free energy.

Start by loading a RET kinase domain structure in the DFG-in active conformation—several are available in the PDB in complex with type I inhibitors. Use the Liganx Studio mutation builder to introduce the G810R substitution, ensuring that side-chain rotamers are sampled to reflect energetically favorable arginine conformations. Dock your inhibitor of interest and compare the resulting pose and predicted affinity to the wild-type complex.

Careful inspection of the solvent-front region will reveal whether the arginine side chain forces the inhibitor into suboptimal binding modes or prevents binding altogether. For medicinal chemists designing RET inhibitors with activity against solvent-front mutants, this workflow provides a structure-based rationale for substituent modifications that avoid clashes with bulky or charged residues at position 810. More detailed guidance on mutation docking protocols is available in our mutation docking guide.

Design Considerations for Solvent-Front Resistance

Overcoming solvent-front mutations requires inhibitors that either tolerate the introduced side chain or bind through alternative modes. One strategy involves reducing inhibitor bulk in the solvent-front–adjacent region, trading some wild-type potency for retained activity against G810 mutants. Another approach exploits alternative binding vectors—type II inhibitors that engage the DFG-out inactive conformation access different pocket geometry and may bypass solvent-front constraints entirely.

Macrocyclic or conformationally constrained scaffolds can preorganize inhibitor geometry to minimize entropic penalties and maximize shape complementarity with mutant pockets. Charged or polar groups strategically positioned to form compensatory interactions with the arginine guanidinium may partially offset unfavorable steric effects. However, designing such compounds requires iterative structure-based optimization and empirical testing in G810-mutant enzyme assays.

Because solvent-front and gatekeeper mutations can co-occur or emerge sequentially, pan-resistance inhibitors ideally retain activity against both classes. This dual constraint significantly narrows chemical space and underscores the value of computational modeling early in hit-to-lead optimization.

Conclusion

RET G810 solvent-front mutations represent a clinically relevant mechanism of resistance to selpercatinib and pralsetinib in RET fusion–driven malignancies. Unlike gatekeeper mutations, solvent-front substitutions disrupt inhibitor binding by introducing steric and electrostatic perturbations at the ATP pocket's solvent-interface region. Structural modeling and mutation-aware docking provide essential tools for dissecting resistance mechanisms and guiding the design of next-generation inhibitors capable of overcoming this resistance class. As the RET inhibitor landscape evolves, understanding the full spectrum of kinase domain mutations—and their distinct structural impacts—will be critical for maintaining durable clinical responses.

References

• Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in RET fusion–positive non–small-cell lung cancer. N Engl J Med. 2020;383(9):813-824. doi:10.1056/NEJMoa2005653
• Gainor JF, Curigliano G, Kim DW, et al. Pralsetinib for RET fusion–positive non–small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021;22(7):959-969. doi:10.1016/S1470-2045(21)00247-3
• Solomon BJ, Tan L, Lin JJ, et al. RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies. J Thorac Oncol. 2020;15(4):541-549. doi:10.1016/j.jtho.2020.01.006
• Rosen EY, Johnson ML, Clifford SE, et al. Overcoming resistance to RET inhibitors in RET fusion–positive lung cancer. Clin Cancer Res. 2021;27(14):4027-4036. doi:10.1158/1078-0432.CCR-20-4981
• Subbiah V, Hu MI, Wirth LJ, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021;9(8):491-501. doi:10.1016/S2213-8587(21)00120-0